Titan Medical : Investor Presentation

Innovation Leader in Robotic Single Access Surgery

Investor Presentation

SEPTEMBER 2021

Nasdaq: TMDI / TSX: TMD

Forward-looking Statements

This presentation contains "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual

Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.comand at www.sec.gov). Information contained in this presentation is qualified in its entirety by such public filings. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the presentation are based upon what management currently believes to be reasonable assumptions as of the date of this presentation, there is no assurance that actual results, performance or achievements will be consistent with these forward-looking statements. This presentation does not constitute an offer to sell any class of securities of the Company in any jurisdiction. There is no assurance as to the whether hospitals will purchase at any assumed prices. The Company does not forecast what portion of the total addressable market it will be able to capture. The Enos™ robotic single access surgical system has not been cleared or approved for marketing or approved for investigational use by the U.S. Food and Drug Administration or any other regulatory authority in any other jurisdiction. This presentation is provided solely for informational purposes.

The data from third-party sources referenced in the footnotes in this presentation speak as of their original publication dates (and not as of the date of this presentation) and the opinions and market data expressed in those reports are subject to change without notice (including without limitation from the intervening impacts of the COVID-19 pandemic). Third-party reports referenced have not been independently verified by the Company and their accuracy, completeness and any underlying assumptions for the market estimate and projections contained therein have not been independently verified. While the Company believes any internal company estimates are reliable, such estimates have not been verified by any independent sources, and the Company does not make any representations as to the accuracy of such estimates.

2

Titan Medical Overview

Titan Medical is a development stage medical device company based in Toronto, Ontario, with an R&D facility in Chapel Hill, North Carolina, focused on robotic assisted surgery (RAS)

Innovation leader in robotic single access surgery

• single access point to reduce trauma to the body, lessen recovery time and diminish scarring

Prospects for key stakeholders

• improve patient outcomes
• optimize surgeon performance
• reduce operating costs

Enos™ Surgical System1

1 The Enos surgical system has not been cleared or approved for marketing in the U.S. or any other jurisdiction

3

Titan Medical Pre-clinical Validation

"The Enos system has evolved at incredible speed, it seems

like this is already the fourth generation, which times perfectly with the market as surgery moves to single port."

Ricardo Estape, MD

GYNECOLOGIC ONCOLOGIST IN MIAMI, FLORIDA

• 7,000+ robotic assisted gynecologic surgeries performed
• Affiliated with medical facilities Baptist Hospital of Miami and Kendall Regional Medical Center
• 20 preclinical procedures performed with the Enos system

4

Titan Medical Highlights

Medtronic Development & License Agreements

• $10M license agreement covering instrument and camera technologies
• $30M co-development and license agreement
• Titan retains worldwide rights to use licensed IP in its Enos system
• Licenses validate Titan's innovations in single access RAS

Preclinical

Evidence

• Enos system validated in 60+ animal and human cadaver studies
• Peer-reviewedabstracts from multiple subspecialities1
• Multi-centerexperience published in Surgical Endoscopy2

Intellectual

Property

• 180+ patents issued or pending
• Early patent filings predate newer RAS entrants
• Comprehensive and growing IP portfolio covering Enos system and more broadly, technologies enabling RAS

1 See website for list at www.titanmedicalinc.com

2Surgical Endoscopy Enabling single-site laparoscopy: the SPORT platform, 2019 Nov;33(11):3696-3703. Barbara Seeliger, Michele Diana, Jelle P. Ruurda, Konstantinos M. Konstantinidis, Jacques Marescaux, Lee L. Swanström

5